Dynamic Technology Lab Private Ltd Makes New $439,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Dynamic Technology Lab Private Ltd bought a new position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 13,717 shares of the company’s stock, valued at approximately $439,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Horizon Advisors Inc. lifted its position in SpringWorks Therapeutics by 47.9% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock worth $45,000 after acquiring an additional 383 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in SpringWorks Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after acquiring an additional 474 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in SpringWorks Therapeutics during the 2nd quarter worth $123,000. Quarry LP lifted its position in SpringWorks Therapeutics by 56.3% during the 2nd quarter. Quarry LP now owns 5,000 shares of the company’s stock worth $188,000 after acquiring an additional 1,800 shares during the last quarter. Finally, Commerce Bank acquired a new position in SpringWorks Therapeutics during the 3rd quarter worth $207,000.

Analyst Ratings Changes

Several research firms have recently issued reports on SWTX. JPMorgan Chase & Co. boosted their price objective on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Evercore ISI began coverage on shares of SpringWorks Therapeutics in a report on Wednesday, November 20th. They set an “outperform” rating and a $60.00 price objective on the stock. HC Wainwright dropped their price objective on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a report on Tuesday, November 12th. Finally, Wedbush restated an “outperform” rating and set a $77.00 price objective on shares of SpringWorks Therapeutics in a report on Monday, November 18th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $69.50.

SpringWorks Therapeutics Stock Down 0.6 %

NASDAQ SWTX opened at $41.48 on Friday. The stock has a market cap of $3.09 billion, a P/E ratio of -10.69 and a beta of 0.79. The company’s 50-day simple moving average is $33.19 and its 200 day simple moving average is $36.79. SpringWorks Therapeutics, Inc. has a twelve month low of $28.00 and a twelve month high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.03. The business had revenue of $49.10 million for the quarter, compared to analysts’ expectations of $53.28 million. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The firm’s revenue for the quarter was up 4810.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.27) earnings per share. Research analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.12 earnings per share for the current year.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.